选择性凝血因子Xa抑制剂:磺达肝癸钠的临床应用研究进展  

Clinical Application of Selective Coagulation Factor Xa Inhibitor:Fondaparinux

作　　者：谢星星 刘学 雷丹丹 余志刚[1] XIE Xingxing;LIU Xue;LEI Dandan;YU Zhigang(Department of Pharmacy,Yaan People’s Hospital,Yaan 625000,Sichuan,China)

机构地区：[1]雅安市人民医院药剂科,四川雅安625000

出　　处：《心血管病学进展》2022年第7期652-656,共5页Advances in Cardiovascular Diseases

基　　金：四川省医学会(恒瑞)科研基金专项科研课题(2021HR26)。

摘　　要：磺达肝癸钠为全球首个人工合成的长效选择性凝血因子Xa抑制剂,多项临床前研究证实其是一种有效和安全的抗凝药物,2001年首次在美国上市,随后分别于2002年和2007年在欧洲和日本上市。迄今为止,已被批准用于静脉血栓栓塞症、急性冠状动脉综合征及深静脉血栓的预防和治疗。近几年,磺达肝癸钠在心房颤动抗凝、肝硬化门静脉血栓形成、新型冠状病毒肺炎患者的抗血栓和抗炎、肝素诱导的血小板减少症的临床应用中也有了长足发展。现综述磺达肝癸钠在上述疾病治疗方面的临床应用,以供临床参考。Fondaparinux is the world’s first synthetic long-acting selective coagulation factor Xa inhibitor and has been proven to be an effective and safe anticoagulant in preclinical studies.It was first listed in the United States in 2001,followed by Europe in 2002 and Japan in 2007.So far,fondaparinux has been approved for the prevention and treatment of venous thromboembolism,acute coronary syndrome and deep vein thrombosis.In recent years,it has also made great progress in the clinical application of anticoagulant in atrial fibrillation,portal venous thromboembolism,anti-thrombotic and anti-inflammatory in patients with COVID-19,and heparin-induced thrombocytopenia.This article reviews the clinical application of fondaparinux in the treatment of the above diseases for clinical reference.

关 键 词：磺达肝癸钠 选择性凝血因子Xa抑制剂 静脉血栓栓塞 心房颤动抗凝 临床应用 

分 类 号：R969[医药卫生—药理学]